Home
Search results “Seattle genetics antibody cures for cancer”
Meet Our Members: Seattle Genetics, Inc.
 
02:35
Seattle Genetics is a biotechnology company focused on developing and commercializing innovative, empowered antibody-based therapies for the treatment of cancer. They are the industry leader in antibody-drug conjugates (ADCs), a technology designed to harness the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. ADCs are intended to spare non-targeted cells and thus reduce many of the toxic effects of traditional chemotherapy, while potentially enhancing antitumor activity. Learn more: http://www.seattlegenetics.com/
Clay Siegall - My Fearless Idea Fights Cancer
 
01:00:05
Clay Siegall tells the story of Seattle Genetics, and the development of antibody-drug conjugates for cancer therapy. Recorded at Bioscience Day 2014 at the University of Maryland.
Views: 1343 UMD Science
Seattle Genetics
 
03:19
Seattle Genetics is passionate about making a positive impact on the lives of patients with cancer and autoimmune diseases. Employees bring that enthusiasm to everything they do, striving to attain their individual goals while recognizing the power of working collaboratively to realize Seattle Genetics' vision of improving patient outcomes. View this career recruitment video to learn about Seattle Genetics' culture and hear directly from chemists, clinical researchers and sales professionals. As a company working at -- and advancing -- the cutting edge of antibody-based therapies, Seattle Genetics fosters an environment that recognizes the challenges of breaking new ground and creates opportunities for intellectual and professional growth. State-of-the art facility gives our team members the resources to succeed. Located in Bothell's Canyon Park area, Seattle Genetics is close to major highways, dining and shopping. If you are passionate about bringing the best of yourself to everything you do, Seattle Genetics offers challenges, opportunities and rewards for making your best even better. We want to hear from you!
Views: 1659 MadDash
Seattle Genetics' Siegall `Excited' by Cancer Drug Data: Video
 
04:39
Oct. 11 (Bloomberg) -- Clay Siegall, chief executive officer of Seattle Genetics Inc., discusses the results from a clinical trial of its SGN-35 drug for treating anaplastic large cell lymphoma. The drug, also known as brentuximab vedotin, uses an antibody to home in on cancer cells. Siegall, speaking with Betty Liu and Adam Johnson on Bloomberg Television's "In the Loop," also discusses the prospects that his company may become a takeover target. (Source: Bloomberg)
Views: 438 Bloomberg
Seattle Genetics
 
02:59
Seattle Genetics is passionate about making a positive impact on the lives of patients with cancer. Employees bring that enthusiasm to everything they do, striving to attain their individual goals while recognizing the power of working collaboratively to realize Seattle Genetics' vision of improving patient outcomes. View this career recruitment video to learn about Seattle Genetics' culture and hear directly from chemists, clinical researchers and sales professionals. As a company working at -- and advancing -- the cutting edge of antibody-based therapies, Seattle Genetics fosters an environment that recognizes the challenges of breaking new ground and creates opportunities for intellectual and professional growth. State-of-the art facility gives our team members the resources to succeed. Located in Bothell's Canyon Park area, Seattle Genetics is close to major highways, dining and shopping. If you are passionate about bringing the best of yourself to everything you do, Seattle Genetics offers challenges, opportunities and rewards for making your best even better. We want to hear from you!
Views: 374 MadDash
Seattle Genetics CEO: Addressing Unmet Needs | Mad Money | CNBC
 
06:39
Seattle Genetics' has put cancer squarely in its sights. Will the pipeline powered by its breakthrough science propel the stock higher? Jim Cramer spoke to CEO Clay Siegall to find out. » Subscribe to CNBC: http://cnb.cx/SubscribeCNBC » Watch more Mad Money here: http://bit.ly/WatchMadMoney » Read more about Seattle Genetics here: http://cnb.cx/2g15k4K "Mad Money" takes viewers inside the mind of one of Wall Street's most respected and successful money managers. Jim Cramer is your personal guide through the confusing jungle of Wall Street investing, navigating through both opportunities and pitfalls with one goal in mind -- to try to help you make money. About CNBC: From 'Wall Street' to 'Main Street' to award winning original documentaries and Reality TV series, CNBC has you covered. Experience special sneak peeks of your favorite shows, exclusive video and more. Get More Mad Money! Read the latest news: http://madmoney.cnbc.com Watch full episodes: http://bit.ly/MadMoneyEpisodes Follow Mad Money on Twitter: http://bit.ly/MadMoneyTwitter Like Mad Money on Facebook: http://bit.ly/LikeMadMoney Follow Cramer on Twitter: http://bit.ly/FollowCramer Connect with CNBC News Online! Visit CNBC.com: http://www.cnbc.com/ Find CNBC News on Facebook: http://cnb.cx/LikeCNBC Follow CNBC News on Twitter: http://cnb.cx/FollowCNBC Follow CNBC News on Google+: http://cnb.cx/PlusCNBC Follow CNBC News on Instagram: http://cnb.cx/InstagramCNBC Seattle Genetics CEO: Addressing Unmet Needs | Mad Money | CNBC
Views: 762 CNBC
Seattle Genetics' Siegall Discusses Lymphoma Treatment: Video
 
02:34
June 8 (Bloomberg) -- Clay Siegall, chief executive officer of Seattle Genetics Inc., talks with Bloomberg's Adam Johnson about clinical trial data for the company's brentuximab vedotin treatment for Hodgkin lymphoma. They speak at the Jefferies 2010 Global Life Sciences Conference in New York. (Source: Bloomberg)
Views: 289 Bloomberg
Seattle Genetics Plunges After Issuing Stage 3 Trial Results
 
01:44
Investors are not reacting favorably to the Seattle Genetics' stage three trial results for its lymphoma treatment.
Seattle Genetics CEO on Front-Line Therapy for Advanced Hodgkin Lymphoma
 
02:19
At the 59th American Society of Hematology (ASH) Annual Meeting and Exposition, Rare Disease Report sat down with Clay Siegall, PhD, CEO of Seattle Genetics, who discussed the ADCETRIS and the evolving paradigm in treatment for patients with advanced Hodgkin lymphoma.
This Cancer Discovery Is A Game Changer
 
03:21
A new experimental treatment has achieved what chemotherapy and bone marrow transplants have failed to do: put chronic, relapsing blood cancers into remission. What's more, it uses the body's own natural defense system to attack these cancerous growths. The treatment involves T cells, a type of immune cell that works as your body's own personal S.W.A.T. team to detect, surround, and destroy foreign invaders like bacteria or viruses. Historically, cancerous cells have grown too fast for T cells to mount an effective defense, and they can also trick T cells into thinking that they’re a healthy part of the body as opposed to a cancerous growth that needs to be stopped. But in experimental treatments at the Fred Hutchinson Cancer Research Center in Seattle, initial evidence shows Dr. Stanley Riddell has successfully trained these T cells to better recognize and eliminate cancer cells in a short time span, allowing cancer to go into remission. Specifically, he extracted a person's T cells in order to prime them to recognize the type of cancer that is affecting the patient, allowing these primed T cells to attack the growth while sparing healthy cells and tissue. Join #FOWLERNATION!! http://bit.ly/SubscribeFowlerNation Become a Patron! http://Patreon.com/FowlerShow 3 Steps To Join #FowlerNation! 1. Subscribe To The Fowler Show: http://bit.ly/SubscribeFowlerNation 2. 'Like' The Richard Fowler Show on Facebook http://www.facebook.com/RichardFowlerShow 3. 'Follow' Us on Twitter http://www.twitter.com/fowlershow These Patrons make the Fowler Show possible ($20+ monthly donation on Patreon.com/FowlerShow) & we couldn't do it without them! Truthservers.com Are you a fan of The Fowler Show? Become a Patron & help support independent media! Learn more here: http://www.patreon.com/fowlershow Want to help out but don't have any money to donate? Donate your account & help us get our stories out on social media. Learn more here: http://www.donateyouraccount.com/fowlershow If you liked this clip, share it with your friends and hit that "like" button! 1,500 Subscriber Behind The Scenes Reward Video - http://www.youtube.com/watch?v=LT9x1PvQTBU Subscribe to our Podcast on iTunes for free! https://itunes.apple.com/us/podcast/the-richard-fowler-show/id510713880 @fowlershow @richardafowler http://www.facebook.com/richardfowlershow http://www.fowlershow.com http://fowlershow.tumblr.com/ Story; http://www.huffingtonpost.com/entry/promising-therapy-sends-93-percent-of-incurable-cancer-into-remission_us_56c3cbf5e4b0c3c550531fe5
Views: 527 The Fowler Show
An Answer to Cancer? Using the immune system to fight cancer -- Longwood Seminar
 
01:32:16
Oncologists are turning to a novel form of therapy to combat cancer: retraining or reengineering the immune system to quash tumor growth. In this seminar, hear from Harvard Medical School scientists and clinicians on the latest approaches that use the body’s own defenses to fight cancer. Speakers: - Arlene Sharpe, MD, PhD - Catherine J. Wu, MD - Jerome Ritz, MD - David F. McDermott, MD Like Harvard Medical School on Facebook: https://goo.gl/4dwXyZ Follow on Twitter: https://goo.gl/GbrmQM Follow on Instagram: https://goo.gl/s1w4up Follow on LinkedIn: https://goo.gl/04vRgY Website: https://hms.harvard.edu/
Views: 10266 Harvard Medical School
Seattle Genetics - New Hire Orientation Video
 
02:28
www.kirklandvideoproduction.com Videography, Editing and Motion Graphics: Rich Rudy Gaffer, Grip, AD: Dahlin Call Synopsis: This is a new hire orientation video for Seattle Genetics. The video was shot on the Canon C100, edited in Premiere Pro, using Photoshop and After Effects for motion graphics. About Seattle Genetics: Seattle Genetics is the largest global oncology biotechnology company based in the Pacific Northwest. We are focused on developing and commercializing a new generation of targeted, empowered antibody-based therapies that have the potential to change the foundation of treatment for people with cancer. For more information about Seattle Genetics, please visit their website at: www.seattlegenetics.com About Kirkland Video Production: Kirkland Video Production is a full service corporate video production company. We offer a wide range of videography services including; shooting, editing, script writing, motion graphics and much more. Whether you need end-to-end video production or you have small bits of the production process that you need to outsource, Kirkland Video Production can handle all your Corporate Videography needs. We've served clients and agencies of all sizes and has a wide range of corporate video experience including producing, writing, shooting and editing all of the following types of videos: TV commercials, marketing videos, non profit fundraiser videos, web videos, event highlight videos, product videos, training videos, TV Shows, and many other custom video projects. Tell use about your next video project! (206)218-7175 rich@kirklandvideoproduction.com
Seattle Genetics Inc. Final Project Engineering Econ
 
09:24
Engineering econ Seattle genetics
Views: 54 BOB Thebuilder
Vol 4. Part 2: Targeting Therapy Utilizing Antibody Drug Conjugates
 
01:51
Watch as Tom Reynolds, Chief Medical Officer of Seattle Genetics, describes the targeted mechanism of action of antibody drug conjugates and their impact on personalized medicine in oncology.
Views: 429 GreenHillHC
A Tipping Point For Cancer Treatment - Healthcare Summit (2014) | Forbes
 
40:12
New approaches in immune treatments and genetic technology mean that we’re making progress in ways that were previously unimaginable. Is vanquishing cancer possible? Subscribe to FORBES: https://www.youtube.com/user/Forbes?sub_confirmation=1 Stay Connected Forbes on Facebook: http://fb.com/forbes Forbes Video on Twitter: http://www.twitter.com/forbesvideo Forbes Video on Instagram: http://instagram.com/forbesvideo More From Forbes: http://forbes.com Forbes covers the intersection of entrepreneurship, wealth, technology, business and lifestyle with a focus on people and success.
Views: 859 Forbes
Dr. Diehl Discusses Brentuximab Vedotin
 
01:52
Volker Diehl, MD, Professor of Medicine, Emeritus, University of Cologne, Germany, discusses the recently approved drug brentuximab vedotin (SGN-35), an antibody-drug conjugate that has been approved to treat anaplastic large cell lymphoma (ALCL) and Hodgkin lymphoma. It is marketed as Adcetris by Seattle Genetics, Inc. Brentuximab vedotin builds on the CD30 tumor marker discovered 30 years ago in cell line L428. CD30 is present in ALCL and Hodgkin lymphoma. The naive monoclonal antibody anti-CD30 is ineffective by itself and requires the combination with another agent to be successful. Diehl describes the chemists at Seattle Genetics as being very intelligent for adding a "bump" to the antibody in the form of monomethyl auristatin E (MMAE), a microtubule inhibitor. Once MMAE enters the CD30-expressing tumor it prevents mitosis within the cells, which causes targeted cell death. The use of brentuximab vedotin in refractory and far advanced relapsing patients with Hodgkin's lymphoma resulted in an approximate complete remission of 35%. This drug is currently being used in combination with Adriamycin (doxorubicin), vinblastine, and dacarbazine (ABVD) in the US. In Germany a new regimen was constructed by modifying BEACOPP (Bleomycin, Etoposide, Adriamycin, Cyclophosphamide, Vincristine, Procarbazine, and Prednisone) in order to incorporate brentuximab vedotin. The modifications leave out procarbazine and long-term prednisone while adding brentuximab vedotin, dacarbazine, and dexamethasone.
Views: 1381 OncLiveTV
Clinical Trial: Phase I CD-352 Antibody, Damian Green MD, Fred Hutchinson Cancer Research Center
 
05:01
A Phase I clinical trial for multiple myeloma patients who have had two lines of treatment including an immunomodulator and proteasome inhibitor. This study is in conjunction with Seattle Genetics
Views: 128 Myeloma Crowd TV
Adcetris
 
16:12
Hodgkin's Lymphoma cured with Adcetris.
Views: 657 Joe Lawyer
Antibody-drug Conjugates - Where are we Going?
 
07:29
Since the approval of the first antibody-drug conjugate or ADC, now more than 15 years ago, scientists and researchers have sent more than 50 ADCs to be clinically evaluated in ongoing clinical research programs. While some of the trial results have indeed been impressive, some of the results have been mixed. At a time when some may worry about a high rate of attrition, researchers have correctly pointed out that a high rate of attrition in phase I and II means that only the best trial drugs advance to phase III trials and beyond. In reviewing the cause of failure of antibody-drug conjugates in clinical trials, researchers are looking at a great number of reasons, including the possibility of linker instability as one possible aspect causing systemic toxicity. But they are also asking if failure may be caused by safety concerns with maximum tolerable dose and low therapeutic index. Why does preclinical data not translate to clinical efficacy in human? Are these problems caused by an insufficient understanding of antibody-drug conjugate metabolism in vivo? In October 2015, during CPhI World Wide in Madrid, Spain we asked experts from Piramal Pharma Solutions, Carbogen Amcis and Catalent about challenges in the manufacturing of ADCs and how they see the market for ADCs evolve. © 2016 Developed and Produced by InPress Media Group, LLC for ADC Review / Journal of Antibody-drug Conjugates
Seattle Genetics Shares Fall Despite Positive Results from Hodgkin's Drug Study
 
00:41
"Shares of Seattle Genetics (SGEN) are off 5%, following positive results from the pivotal trial of single-agent brentuximab vedotin (SGN-35) in relapsed or refractory Hodgkin lymphoma. The results are better than expected, but the commercial potential of the drug may be limited because of ""the small market opportunity,"" Bloomberg reported, citing Canaccord Genuity analyst George Farmer. Seattle Genetics shares are down 5.23%, or $0.83, to $15.04."
Views: 179 FinancialNewsOnline
John Schiller (NCI at NIH) 1: Human Papillomavirus (HPV) Vaccines to Prevent Cancer
 
32:44
https://www.ibiology.org/human-disease/hpv John Schiller provides an overview of HPV virus and infection, compares the three FDA approved vaccines against HPV, and explains the endpoints used in the clinical trials to prove vaccine efficacy. Talk Overview: Human Papillomavirus (HPV) causes 5% of all cancers worldwide, and the first vaccine against HPV was approved in 2006. In this seminar, Dr. John Schiller provides an overview of HPV virus and infection, compares the three FDA approved vaccines against HPV, and explains the endpoints used in the clinical trials to prove vaccine efficacy. After a decade of using the vaccine, retrospective studies now allow us to evaluate the possibility of using single-dose vaccination, which could lead to an increase in the general use of the vaccine (implementation), and improve HPV-related cancer prevention. In his second seminar, Schiller discusses the high efficacy of HPV vaccine, which is exceptionally good at producing neutralizing antibodies and also benefits from the low mutation rate of HPV. Coming to a better understanding of the efficacy of the HPV vaccine will provide evidence to support single-dose vaccination and aids in the development of new vaccines. Speaker Biography: Dr. John Schiller is a National Institute of Health (NIH) distinguished investigator and a professor at the National Cancer Institute at the NIH. Schiller completed his bachelor’s degree in molecular biology at the University of Wisconsin-Madison (1975), and received a doctorate degree in Microbiology at the University of Washington in Seattle (1982). Schiller continued his training at the Laboratory of Cellular Oncology as a National Research Service Award postdoctoral fellow. He became a senior investigator in 1986, and in 2016 he was designated as an NIH Distinguished Investigator. For his scientific contributions, Schiller received the National Medal of Technology and Innovation (2012), the American Society for Microbiology’s Joseph Public Health Award (2017), and the Lasker-DeBakey Clinical Medical Research Award (2017). Learn more about Schiller’s research at his lab website: https://ccr.cancer.gov/Laboratory-of-Cellular-Oncology/john-t-schiller
Views: 1673 iBiology
Seattle Genetics Time Lapse video
 
02:31
Perlow Productions provided HD videography and video editing for this time lapse marketing video production. Learn more about Perlow Productions at www.perlowproductions.com .
Views: 81 PerlowProductions
Improving Targeted Therapies for Patients with Previously Untreated Advanced Classic Hodgkin Lymphom
 
40:01
Source: https://www.spreaker.com/user/7078249/joseph-connors-interview In this episode of The Onco'Zine Brief, Peter Hofland, Ph.D and Sonia Portillo talk with Dr. Joseph M. Connors, MD., FRCPC, Clinical Professor in the Department of Medicine, Division of Medical Oncology, at the University of British Columbia and the chair of the Lymphoma Tumor Group for the British Columbia Cancer Agency. Dr. Connors is also the lead investigator of the ECHELON-1 clinical trial, a trial focusing on a new treatment option for Hodgekin Lymphoma. In this interview Hofland and Portillo talks with Dr. Connor about some of the latest results from the ECHELON-1 clinical trial, which tests an antibody-drug conjugate or ADC called brentuximab vedotin (ADCETRIS; being developed by Seattle Genetics and Takeda), as a frontline treatment option for patients with advanced classical Hodgkin Lymphoma. They also talk with Dr. Connors about how the ECHELON-1 study was conducted, and why it is important for this patient group, and for cancer research as a whole.
(SGEN) Seattle Genetics, Inc.
 
05:21
(SGEN) Seattle Genetics, Inc.
Views: 96 Bill Gunderson
Healthy Outlook?
 
06:17
Seattle Genetics' has put cancer squarely in the sites of its targeted treatment technology. Will the pipeline powered by this breakthrough science propel its stock higher? Mad Money's Jim Cramer interviews the CEO.
Views: 531 CNBC
V4P8: Cost Effectiveness of Antibody Drug Conjugate Technology
 
01:31
In Part 8 of our Interview with the Innovators series with Tom Reynolds, Chief Medical Officer of Seattle Genetics, focuses on the cost effectiveness and impact in the community.
Views: 119 GreenHillHC
Seattle Genetics
 
02:01
VIDEO FINANCIAL REPORTING Why invest in is the first financial video platform where you can easily search through thousands of videos describing global securities. About The Video: We believe that complex financial data could become more approachable using friendly motion-graphic representation combined with an accurate selection of financial data. To guarantee the most effective information prospective we drew inspiration from Benjamin Graham’s book: “The Intelligent Investor”, a pillar of financial philosophy. For this project any kind of suggestion or critic will be helpful in order to develop and provide the best service as we can. Please visit our site www.whyinvestin.com and leave a massage to us. Thank you and hope you'll enjoy. IMPORTANT INFORMATION - DISCLAIMER THIS VIDEO IS FOR INFORMATION PURPOSES ONLY AND SHOULD NOT BE RELIED UPON AS INVESTMENT ADVICE. This video has been prepared by Whyinvestin (together with its affiliates, “Whyinvestin”) and is not intended to be taken by, and should not be taken by, any individual recipient as investment advice, a recommendation to buy, hold or sell any security, or an offer to sell or a solicitation of offers to purchase any security. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. The performance of the companies discussed on this video is not necessarily indicative of the future performances. Investors should consider the content of this video in conjunction with investment reports, financial statements and other disclosures regarding the valuations and performance of the specific companies discussed herein. DO NOT RELY ON ANY OPINIONS, PREDICTIONS OR FORWARD-LOOKING STATEMENTS CONTAINED HEREIN. Certain of the information contained in this video constitutes “forward-looking statements” that are inherently unreliable and actual events or results may differ materially from those reflected or contemplated herein. None of Whyinvestin or any of its representatives makes any assurance as to the accuracy of those predictions or forward-looking statements. Whyinvestin expressly disclaims any obligation or undertaking to update or revise any such forward-looking statements. EXTERNAL SOURCES. Certain information contained herein has been obtained from third-party sources. Although Whyinvestin believes such sources to be reliable, we make no representation as to its accuracy or completeness. FINANCIAL DATA. Historical companies’ data, ratios, exchange rate, prices and estimates are provided by Factset research www.factset.com . Whyinvestin does not verify any data and disclaims any obligation to do so. Whyinvestin, its data or content providers, the financial exchanges and each of their affiliates and business partners (A) expressly disclaim the accuracy, adequacy, or completeness of any data and (B) shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon. Neither Whyinvestin nor any of our information providers will be liable for any damages relating to your use of the information provided herein. Please consult your broker or financial representative to verify pricing before executing any trade. Whyinvestin cannot guarantee the accuracy of the exchange rates used in the videos. You should confirm current rates before making any transactions that could be affected by changes in the exchange rates. You agree not to copy, modify, reformat, download, store, reproduce, reprocess, transmit or redistribute any data or information found herein or use any such data or information in a commercial enterprise without obtaining prior written consent. Please consult your broker or financial representative to verify pricing before executing any trade. COPYRIGHT “FAIR USE” Whyinvestin doesn’t own any logo different from the whyinvestin’ s logo contained in the video. The owner of the logos is the subject of the video itself (the company); and all the logos are not authorized by, sponsored by, or associated with the trademark owner . Whyinvestin uses exclusive rights held by the copyright owner for Educational purposes and for commentary and criticism as part of a news report or published article. If you are a company, subject of the video and for any reason want to get in contact with Whyinvestin please email: company@whyinvestin.com
Views: 12 Why Invest In
Dr. Fanale Discusses Antibody-Drug Conjugates
 
01:48
Michelle A. Fanale, MD, Associate Professor, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the role of antibody-drug conjugates. For more information and resources about targeted therapies in cancer: http://targetedhc.com/
Views: 115 Targeted Oncology
News Update: Seattle Genetics Tumbles 4% After Leukemia Drug Trials Fail
 
00:53
Seattle Genetics (NASDAQ:SGEN) is trading 4% lower Monday after the company reported its leukemia drug known as lintuzumab, failed its trial, and that it has opted to discontinue development. Specifically, the key trial showed that the biotechnology treatment did not extend the lives of patients with acute myeloid leukemia. The drug was licensed by Seattle Genetics in 2005 when PDL BioPharma Inc (NASDAQ:PDLI) decided to not pursue the antibody following disappointing results from leukemia trials. SmarTrend currently has Seattle Genetics in a Downtrend and is currently monitoring these developments and will alert subscribers to any change of trend.
Views: 220 TradeTheTrend
V4P5: ADCs: Part of the Renaissance of Targeted Therapy and  Personalized Medicine Approaches
 
01:10
Watch as Tom Reynolds, Chief Medical Officer of Seattle Genetics, describes the renaissance of targeted therapy and personalized medicine approaches and where antibody drug conjugates fit into this spectrum.
Views: 44 GreenHillHC
CIPO2015: Anti-GD2 mAb and Next Generation mAb-Based Agents, KIR, Cytokines and Combination Therapy
 
32:50
Dr. Paul M. Sondel of University of Wisconsin–Madison speaks about antibody-based therapies for childhood cancers at the 4th International Conference on Immunotherapy in Pediatric Oncology (CIPO2015), hosted by Seattle Children’s Research Institute. Dr. Sondel shares how combined immunotherapies can prevent relapse when used to treat microscopic disease, and how combining immunotherapies with local delivery can eradicate macroscopic disease. Paul M. Sondel, MD, PhD, Reed and Carolee Walker Professor in Pediatric Oncology, University of Wisconsin–Madison 09/26/2015 http://www.seattlechildrens.org/research/ http://www.seattlechildrens.org/research/childhood-cancer/CIPO-2015/ http://uwtv.org
Views: 507 UWTV
A New Frontline Treatment Option for Hodgekin Lymphoma
 
40:01
Source: https://www.spreaker.com/user/7078249/joseph-connors-interview_1 In this Edition of The Onco'Zine Brief Peter Hofland, Ph.D and Sonia Portillo talk with Joseph M. Connors, MD., FRCPC, Clinical Director, Center for Lymphoid Cancer (Retired 2018) and Clinical Professor in the Department of Medicine, Division of Medical Oncology, at the University of British Columbia and the chair of the Lymphoma Tumor Group for the British Columbia Cancer Agency Dr. Connors is also the lead investigator of the ECHELON-1 clinical trial, a trial focusing on a new treatment option for Hodgekin Lymphoma. In this interview Dr. Connor talks about the some of the latest results from the ECHELON-1 clinical trial, which tests an antibody-drug conjugate or ADC called brentuximab vedotin (Adcetris; Seattle Genetics/Takeda) for patients with advanced classical Hodgkin Lymphoma. The phase III ECHELON-1 study, was designed to evaluate brentuximab vedotin as part of a front-line chemotherapy regimen for previously untreated advanced classic Hodgkin lymphoma. The trial met its primary endpoint of modified progression-free survival in 2017. The latest data from the study was presented during the 2017 American Society of Hematology Annual Meeting & Expostion and simultaneous publication in The New England Journal of Medicine. Now, brentuximab vedotin is an approved drug and commercially available in the United States. The ECHELON-1 trial was important for the approval by the FDA of a so called ‘fifth approval or line expansion’ of the drug.
Conquering Cancer: Personalized Cancer Care
 
01:25:03
Session Chair: Michael B. Yaffe, David H. Koch Institute for Integrative Cancer Research at MIT; Professor, Departments of Biology and Biological Engineering, MIT; Senior Associate, Broad Institute Panel: Daniel A. Haber SB '77 SM '77, Director, Massachusetts General Hospital Cancer Center; Isselbacher/Schwartz Professor, Harvard Medical School; Investigator, Howard Hughes Medical Institute Michael T. Hemann, David H. Koch Institute for Integrative Cancer Research at MIT; Latham Family Career Development Assistant Professor of Biology, MIT David M. Livingston, Emil Frei Professor of Genetics and Medicine, Harvard Medical School; Deputy Director, Dana-Farber/Harvard Cancer Center; Chief, Charles A. Dana Division of Human Cancer Genetics Corbin Elizabeth Meacham, G, David H. Koch Institute for Integrative Cancer Research at MIT; Department of Biology, MIT
V4P9: Relationship Between Biomarker Prevalence  and the Targeted Therapy
 
01:15
Tom Reynolds, Chief Medical Officer of Seattle Genetics, discusses how best to identify patients who will respond to antibody drug conjugate therapy in Part 9 of our Interview with the Innovators series.
Views: 40 GreenHillHC
V4 P4: Advantages of Antibody Drug Conjugates
 
01:55
Tom Reynolds, Chief Medical officer of Seattle Genetics, describes the advantages of antibody drug conjugates in this next segment of our Interview with the Innovators.
Views: 232 GreenHillHC
New US breast cancer drug
 
01:35
Subscribe to our channel http://bit.ly/AJSubscribe Subscribe to our channel http://bit.ly/AJSubscribe Touted as a major victory in the battle against breast cancer, researchers in the United States have announced a new class of chemotherapy drug. Scientists describe it as an "armed antibody", TDM1 is a "magic bullet" treatment, killing cancer cells without destroying the patients' quality of life. Al Jazeera's Anand Naidoo reports from Washington. At Al Jazeera English, we focus on people and events that affect people's lives. We bring topics to light that often go under-reported, listening to all sides of the story and giving a 'voice to the voiceless.' Reaching more than 270 million households in over 140 countries across the globe, our viewers trust Al Jazeera English to keep them informed, inspired, and entertained. Our impartial, fact-based reporting wins worldwide praise and respect. It is our unique brand of journalism that the world has come to rely on. We are reshaping global media and constantly working to strengthen our reputation as one of the world's most respected news and current affairs channels. Social Media links: Facebook: https://www.facebook.com/aljazeera Instagram: https://instagram.com/aljazeera/?ref=... Twitter: https://twitter.com/ajenglish Website: http://www.aljazeera.com/ google+: https://plus.google.com/+aljazeera/posts
Views: 1634 Al Jazeera English
New Lymphoma Drug SGN-35 - The Nebraska Medical Center
 
04:32
"This is really a breakthrough in that we finally have something to treat these really difficult to treat patients." The FDA approved SGN-35 as a treatment for Hodgkin's Lymphoma in August 2011. It is the first FDA-approved Hodgkin's treatment since 1977. The drug is also used to treat other rare types of lymphoma such as t-cell non-Hodgkin's Lymphoma. The drug is mono-clonal antibody which attacks a protein on the surface of a lymphoma cell. It seeks out the cancer cell directly and spares the normal healthy cells. It is given through the vein once every three weeks. In some cases, SGN-35 can be used to get a patient ready to undergo a stem cell transplant. The Nebraska Medical Center and its education and research partner, the University of Nebraska Medical Center have been international leaders in lymphoma and leukemia treatment and research for decades, in many cases pioneering treatments used around the world. As one of the medical centers involved in the clinical trials of SGN-35, the medical center's team has experience with this new treatment. For more information about the hematology/oncology program at The Nebraska Medical Center, visit http://www.nebraskamed.com/cancer or call 1-800-922-0000.
Views: 2021 Nebraska Medicine
Antibody Mediated Targeted Therapies
 
15:20
speaker - Dr. Irmgard Thorey, Senior Scientist, Lead Identification, Roche Innovation Center Penzberg, Roche Diagnostics GmbH, Penzberg (D) "Pharmaceutical Development of Nanomedicine Medications" Chair - Dr. Bernd Riebesehl, Principal Fellow, Novartis Pharma AG, Basel (CH). Day 2 Hall Singapore The European Summit for Clinical Nanomedicine and Targeted Medicine – The Translation to Knowledge Based Medicine Eighth Conference and Exhibition, June 28 – July 1, 2015. CLINAM 30.06.2015
Views: 113 TAUVOD
How “living drugs” could help us fight cancer | Chiara Bonini | TEDxLUISS
 
17:42
Chiara is working on a revolutionary immunotherapy approach to fight cancer which involves the use of genetically engineered lymphocytes as "living drugs". Even if the journey has just started, Chiara’s enthusiasm toward research will lead you towards a world of hope where everything is possible if you can share your challenges with the right team. Chiara Bonini’s slides have been designed by some students from the “Fondazione Sacro Cuore” Artistic High-School, Milan. Chiara Bonini is Professor at the School of Medicine, Università Vita-Salute, San Raffaele, and Vice Director for the Division of Immunology, Transplantation and Infectious Diseases at the Ospedale San Raffaele Scientific Institute, Milan, Italy. Chiara Bonini is Vice Director for the Division of Immunology, Transplantation and Infectious Diseases and Head of the Experimental Hematology Unit at San Raffaele Institute, Milan, Italy. She is also Assistant Professor at the School of Medicine, School of Biotechnology, Università Vita-Salute, San Raffaele, Milan, Italy. This talk was given at a TEDx event using the TED conference format but independently organized by a local community. Learn more at http://ted.com/tedx
Views: 830 TEDx Talks
New therapies for high risk Neuroblastoma
 
47:03
Professor Julie Park Seattle Children's Hospital
Vol. 4 Part 12: The Importance of Intercompany Collaborations within the Industry
 
01:18
Part 12 of our Interview with the Innovators series with Tom Reynolds, Chief Medical Officer of Seattle Genetics, focuses on the importance of intercompany collaboration in bringing targeted therapy with antibody drug conjugates to the oncology treatment landscape.
Views: 54 GreenHillHC
Vol. 4 Part 10: Regulatory Challenges with ADC Technology
 
01:39
What are the regulatory challenges in bringing antibody drug conjugates to market? Watch as Tom Reynolds, Chief Medical Officer of Seattle Genetics, describes the challenges and issues in this next video segment.
Views: 183 GreenHillHC
Dr. Fanale on Brentuximab Vedotin as Frontline Treatment for Lymphoma
 
01:33
Michelle A. Fanale, MD, Associate Professor, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the role of brentuximab vedotin as frontline treatment of systemic anaplastic large cell lymphoma (ALCL). For more ASH 2012 coverage: http://www.onclive.com/conference-coverage/ash-2012
Views: 171 Targeted Oncology
Dr. Zelenetz Discusses Brentuximab Vedotin
 
00:42
Andrew D. Zelenetz, MD, Chief, Lymphoma Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, Associate Professor of Medicine, Weill Cornell Medical College, believes that brentuximab vedotin (Adcetris), an antidrug conjugate, represents a very exciting treatment for patients. The FDA approved brentuximab vedotin to treat two types of lymphoma. The first indication came for refractory anaplastic large cell lymphoma and the second for Hodgkin lymphoma (HL) after the failure of either autologous stem cell transplant (ASCT) or 2 or more multi-agent chemotherapy regimens. Investigators are actively developing brentuximab vedotin to find new indications earlier in the treatment course. Zelenetz notes that if a benefit exists in early-stage HL then ASCT could be avoided in the relapsed or refractory setting.
Views: 334 OncLiveTV
GENE THERAPY IN A BOX
 
01:04:15
defeatHIV educational webinar with Dr, Jennifer Adair at Fred Hutch,who talks about her research into a portable machine-- 'gene therapy in a box'-- that could make future cancer & HIV cures affordable in developing countries. “We either had to think about how to build million-dollar infrastructure and clean-room facilities in clinics all around the world, which is not feasible, or we had to think about simplifying this process into what I originally envisioned as a black box,” said Fred Hutch researcher Dr. Jennifer Adair. A tabletop device that enables medical staff to genetically manipulate a patient’s blood to deliver potential new therapies for cancer, HIV and other diseases would eliminate the need for multimillion-dollar “clean rooms,” making gene therapy more possible for even the poorest of countries. The so-called “gene therapy in a box,” developed by scientists at Fred Hutchinson Cancer Research Center, delivers modified blood stem cells that were as good as — or better — than those manufactured in highly regulated clean rooms and requires less than half the staff, according to a study published in Nature Communications. The adapted cells also successful repopulated the blood system when tested in two different animal models, the study noted. It hasn’t yet been tested in humans. This video was recorded on February 17, 2016 at Fred Hutch.
Views: 222 defeatHIV
Antibody-Drug Conjugates: Engineering for Safety & Success
 
01:44
▶ CLICK TO ORDER: http://www.chi-peptalk.com/peptalk_content.aspx?id=125057 This course provides a detailed look into the discovery, characterization, and manufacturing of Antibody-Drug Conjugates, with a particular focus on safety issues. Featured is an in-depth and extensive case study from Genentech about their use of antibody-drug conjugates in a robust bio-oncology program, including a focus on risk mitigation and risk minimization strategies. This talk is followed by a presentation about Sutro Biopharma's Open Cell Free Synthesis (OCFS) technology for screening, selecting and formulating ADCs. Finally, an excellent overview of the infrastructure required to produce these molecules is presented by Lonza. All three presentations are filled with first-hand insights and practical approaches to successfully developing these potent biologics.
Views: 443 CambridgeHealthtech